NURO NeuroMetrix Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: NURO

Price (delayed)

$3.93

Market cap

$4.22M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$5.52

Enterprise value

$3.03M

NeuroMetrix is an innovation-driven company focused on the development and global commercialization of non-invasive medical devices for the diagnosis and treatment of disorders involving the nervous system. The Company has ...

Highlights
NeuroMetrix's debt has decreased by 29% YoY and by 10% QoQ
NURO's EPS is up by 2.8% QoQ and by 2.8% YoY
NURO's quick ratio is up by 23% year-on-year but it is down by 14% since the previous quarter
NeuroMetrix's gross profit has decreased by 25% YoY and by 10% from the previous quarter
NURO's revenue is down by 22% year-on-year and by 11% since the previous quarter
Sector: Healthcare
Industry: Medical Instruments & Supplies
Website: http://www.neurometrix.com
Peers: IART SYK MDT

Key stats

What are the main financial stats of NURO
Market
Shares outstanding
1.07M
Market cap
$4.22M
Enterprise value
$3.03M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
0.21
Price to sales (P/S)
0.66
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
0.47
Earnings
Revenue
$6.43M
EBIT
-$5.57M
EBITDA
-$5.53M
Free cash flow
-$6.26M
Per share
EPS
-$5.52
Free cash flow per share
-$5.83
Book value per share
$18.56
Revenue per share
$6
TBVPS
$19.85
Balance sheet
Total assets
$21.29M
Total liabilities
$1.38M
Debt
$271,261
Equity
$19.9M
Working capital
$19.45M
Liquidity
Debt to equity
0.01
Current ratio
16.43
Quick ratio
14.48
Net debt/EBITDA
0.22
Margins
EBITDA margin
-86%
Gross margin
67.3%
Net margin
-86.6%
Operating margin
-95.6%
Efficiency
Return on assets
-24.1%
Return on equity
-25.7%
Return on invested capital
-28.4%
Return on capital employed
-27.8%
Return on sales
-86.6%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

NURO stock price

How has the NeuroMetrix stock price performed over time
Intraday
-3.98%
1 week
-7.31%
1 month
-3.68%
1 year
-70.58%
YTD
-67.03%
QTD
-31.43%

Financial performance

How have NeuroMetrix's revenue and profit performed over time
Revenue
$6.43M
Gross profit
$4.33M
Operating income
-$6.15M
Net income
-$5.57M
Gross margin
67.3%
Net margin
-86.6%
NURO's operating margin has shrunk by 61% YoY and by 17% QoQ
NeuroMetrix's net margin has shrunk by 51% YoY and by 15% QoQ
NURO's operating income is down by 26% year-on-year and by 4.2% since the previous quarter
NeuroMetrix's gross profit has decreased by 25% YoY and by 10% from the previous quarter

Growth

What is NeuroMetrix's growth rate over time

Valuation

What is NeuroMetrix stock price valuation
P/E
N/A
P/B
0.21
P/S
0.66
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
0.47
NURO's EPS is up by 2.8% QoQ and by 2.8% YoY
The P/B is 83% below the 5-year quarterly average of 1.2 and 48% below the last 4 quarters average of 0.4
The equity has declined by 9% year-on-year and by 7% since the previous quarter
The stock's price to sales (P/S) is 61% less than its 5-year quarterly average of 1.7 and 45% less than its last 4 quarters average of 1.2
NURO's revenue is down by 22% year-on-year and by 11% since the previous quarter

Efficiency

How efficient is NeuroMetrix business performance
NURO's ROS has shrunk by 51% YoY and by 15% QoQ
The ROIC has grown by 38% YoY but it has contracted by 6% from the previous quarter
NURO's ROA is down by 28% YoY and by 6% from the previous quarter
NeuroMetrix's ROE has decreased by 26% YoY and by 5% from the previous quarter

Dividends

What is NURO's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for NURO.

Financial health

How did NeuroMetrix financials performed over time
NURO's total liabilities is down by 33% YoY
The current ratio has grown by 28% YoY but it has contracted by 11% from the previous quarter
NeuroMetrix's debt is 99% lower than its equity
NURO's debt to equity has dropped by 50% year-on-year
NeuroMetrix's debt has decreased by 29% YoY and by 10% QoQ

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.